How Effective is Cannabis THC-Based Dronabinol for Sleep Apnoea?

PostedMarch 5, 2026

UpdatedMarch 5, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Obstructive sleep apnoea (OSA) can severely disrupt sleep and impact overall health. Researchers are investigating dronabinol for sleep apnoea, a THC-based therapy, to determine its potential benefits in reducing nightly breathing interruptions. Understanding its role in THC treatment for OSA is increasingly important.

Potential Benefits of Dronabinol in OSA

Early studies suggest dronabinol for sleep apnoea may improve airway stability and reduce apnoeic events.

Respiratory Support

Dronabinol may influence neural control of airway muscles, contributing to better airflow and supporting cannabinoid therapy for sleep.

Sleep Continuity

Patients using dronabinol for sleep apnoea have reported fewer awakenings, enhancing overall sleep quality.

Dose-Dependent Effect

Effectiveness of THC treatment for OSA may vary with dose, highlighting the need for careful titration.

Daytime Alertness Improvement

Reduced night-time apnoeas may lead to less daytime fatigue, indirectly reflecting cannabinoid therapy for sleep benefits.

Adjunctive Use

Dronabinol could complement standard OSA interventions, offering a combined approach for symptom management.

While dronabinol for sleep apnoea shows promise in reducing apnoeic events and supporting THC treatment for OSA, further research is required to confirm long-term safety, optimal dosing, and integration into cannabinoid therapy for sleep plans.

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea .

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.